A neutral, harm-reduction guide to amycretin, an investigational GLP-1/amylin agonist in oral and injectable forms, entering Phase 3.
At a glance
Best for
Amycretin is a single-molecule (unimolecular) GLP-1 and amylin receptor agonist developed by Novo Nordisk, notable for being studied in both subcutaneous and oral forms. By combining GLP-1 and amylin activity in one molecule, it aims to stack two satiety pathways for stronger appetite suppression. Early-phase data published in The Lancet showed substantial weight loss, and in 2025 Novo Nordisk announced plans to advance both the injectable and oral forms into Phase 3 development, beginning in 2026.
Amycretin is investigational and not approved. This is an educational tracking guide, not medical advice or a recommendation.
In the early trials, amycretin was dose-escalated to manage gastrointestinal tolerability. Because both an oral and a subcutaneous version exist, administration details differ by form, and the oral version would be expected to carry absorption-related timing considerations. All dosing here is trial context, not a recommendation.
The early numbers are encouraging but come from small, early-phase studies. Late-stage trials will define real efficacy and safety. As with any effective weight-loss agent, part of rapid loss can be lean mass, so protein and resistance training deserve tracking.
Amycretin is investigational, with a risk profile still being established in trials. Expect GLP-1 and amylin class GI effects, and treat any access outside a clinical trial as outside the evidence base. Use only with medical supervision.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.